Jolt Health Inc. Terminates Acquisition Agreement and Shifts Focus to AI Opportunities

VANCOUVER, BC / ACCESSWIRE / June 10, 2024 / Jolt Health Inc. (CSE:JOLT)(FSE:G1Q0) has announced the termination of its planned acquisition of transdermal delivery technology for chloroquine and hydroxychloroquine. The decision aligns with the company's revised strategic priorities.

Jolt Health is now concentrating on opportunities within the rapidly growing artificial intelligence (AI) sector. The company aims to leverage AI to drive innovation in healthcare and biotechnology, in line with its mission to transform the industry through advanced solutions.

CEO Gerald Tritt stated, "We appreciate the efforts of all parties involved in the initial agreement. Our focus is now on AI to enhance our health and wellness portfolio." Tritt also noted optimism due to recent interest rate cuts, which support the company’s growth initiatives.

Jolt Health holds exclusive licenses for therapeutic products across Europe, the UK, and North America. The company remains committed to advancing healthcare through research and technological advancements.